El Tayebi received her bachelor's degree with highly honored excellence from the Faculty of Pharmacy and Biotechnology, GUC, in 2008. In 2009, she was appointed as an assistant lecturer of molecular pathology and pathophysiology at the GUC. In 2014, she started teaching cell biology and genetic engineering as an assistant professor. From 2008 to 2012, she pursued her M.Sc. and Ph.D. studies in the field of molecular pharmacology. She received her Ph.D. degree “summa cum laude” from the GUC in 2012. After receiving her Ph.D., Hend worked as a post-doctoral fellow in the Molecular Pathology Research Group where she was leading the Hepatocellular Carcinoma (HCC) Subteam. She established the Molecular Pharmacology Research Group at the GUC in 2015. Throughout her academic career, El Tayebi has been invited as a guest speaker at more than 15 international conferences in Europe and the MENA region, published and presented her research work at several international conferences in Europe and the USA (EASL, ESMO, Falling Wall of Berlin, EMBL, ADSL, and APASL), and she published more than 20 paper publications in peer-reviewed international journals, in addition to several books and book chapter publications. El Tayebi and her team focus on epigenetic immuno-oncology and molecular regulation of certain immuno-modulatory proteins in liver and breast cancer. In 2018, autoimmunity and multiple sclerosis (MS) were added as new research interests.
El Tayebi received her bachelor's degree with highly honored excellence from the Faculty of Pharmacy and Biotechnology, GUC, in 2008. In 2009, she was appointed as an assistant lecturer of molecular pathology and pathophysiology at the GUC. In 2014, she started teaching cell biology and genetic engineering as an assistant professor. From 2008 to 2012, she pursued her M.Sc. and Ph.D. studies in the field of molecular pharmacology. She received her Ph.D. degree “summa cum laude” from the GUC in 2012. After receiving her Ph.D., Hend worked as a post-doctoral fellow in the Molecular Pathology Research Group where she was leading the Hepatocellular Carcinoma (HCC) Subteam. She established the Molecular Pharmacology Research Group at the GUC in 2015. Throughout her academic career, El Tayebi has been invited as a guest speaker at more than 15 international conferences in Europe and the MENA region, published and presented her research work at several international conferences in Europe and the USA (EASL, ESMO, Falling Wall of Berlin, EMBL, ADSL, and APASL), and she published more than 20 paper publications in peer-reviewed international journals, in addition to several books and book chapter publications. El Tayebi and her team focus on epigenetic immuno-oncology and molecular regulation of certain immuno-modulatory proteins in liver and breast cancer. In 2018, autoimmunity and multiple sclerosis (MS) were added as new research interests.